Cross-national study of women's use of hormone replacement therapy (HRT) in Europe

被引:0
作者
Schneider, HPG
机构
来源
INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE | 1997年 / 42卷
关键词
hormone replacement therapy; menopause;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The benefits of hormone replacement therapy (HRT) to perimenopausal and postmenopausal women are well established. Women from France, Germany, Spain, and the United Kingdom were interviewed to determine: (1) knowledge and views of menopause and HRT; (2) history of HRT among current and lapsed users; and (3) reasons of non-users for never having taken HRT. In 1996, nearly 1,500 women aged 40 to 65 answered a short series of questions concerning menopause and HRT as part of a consumer omnibus survey; others (n = 929) participated in a focused survey of attitudes toward and use of HRT. Only one-third of perimenopausal and 13% of postmenopausal women currently were taking HRT. About 25% of postmenopausal women reported having taken HRT at some time. The proportion of perimenopausal women using HRT varied by country, and ranged from 18% in Spain to 55% in France. Importantly, about half (range across countries, 38% to 61%) of the women interviewed had not discussed menopause or its symptoms with their doctors. While levels of HRT knowledge varied by country, two-thirds of respondents overall believed they needed more information about HRT. Decisions about beginning HRT and choosing a formulation were viewed by most women as matters of personal choice, to be made with advice from a physician. In summary, despite the benefits of HRT and available choices among drug delivery options, a fairly small proportion of European women use it, largely because most remain poorly informed about the therapy. Increased physician-patient communication and public education programs are needed to provide women with the information they need to make judicious decisions concerning HRT.
引用
收藏
页码:365 / 375
页数:11
相关论文
共 33 条
[1]   CONTINUOUS COMBINED ESTROGEN-PROGESTIN HORMONE REPLACEMENT THERAPY [J].
ANDREWS, WC .
CLINICAL THERAPEUTICS, 1995, 17 (05) :812-826
[2]  
Bachmann G A, 1995, Int J Fertil Menopausal Stud, V40 Suppl 1, P16
[3]   TRANSDERMAL ESTRADIOL - A REVIEW OF ITS PHARMACOLOGICAL PROFILE, AND THERAPEUTIC POTENTIAL IN THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS [J].
BALFOUR, JA ;
MCTAVISH, D .
DRUGS & AGING, 1992, 2 (06) :487-507
[4]   WOMENS OPINION ON WITHDRAWAL BLEEDING WITH HORMONE REPLACEMENT THERAPY [J].
BARENTSEN, R ;
GROENEVELD, FPMJ ;
BAREMAN, FP ;
HOES, AW ;
DOKTER, HJ ;
DROGENDIJK, AC .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1993, 51 (03) :203-207
[5]  
Barrett-Connor E, 1993, Int J Fertil Menopausal Stud, V38 Suppl 1, P6
[6]   ESTROGEN REPLACEMENT THERAPY AND RISK OF FATAL COLON-CANCER IN A PROSPECTIVE COHORT OF POSTMENOPAUSAL WOMEN [J].
CALLE, EE ;
MIRACLEMCMAHILL, HL ;
THUN, MJ ;
HEATH, CW .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (07) :517-523
[7]  
CANO A, 1995, MATURITAS, V20, P90
[8]  
Doren M, 1996, INT J FERTIL MENOP S, V41, P29
[9]   PERIMENOPAUSAL WOMENS VIEWS ON TAKING HORMONE REPLACEMENT THERAPY TO PREVENT OSTEOPOROSIS [J].
DRAPER, J ;
ROLAND, M .
BRITISH MEDICAL JOURNAL, 1990, 300 (6727) :786-788
[10]   Hormone replacement therapy and diabetes mellitus [J].
Dunne, FP ;
Harris, P ;
Keane, L ;
Jenkins, D ;
Wright, AD .
CLINICAL ENDOCRINOLOGY, 1996, 44 (06) :615-620